Close: closure of patent foramen ovale, ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Close: closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: study design
Auteur(s) :
Mas, Jean-Louis [Auteur]
Derumeaux, Genevieve [Auteur]
Amarenco, Pierre [Auteur]
Arquizan, Caroline [Auteur]
Aubry, Pierre [Auteur]
Barthelet, Martine [Auteur]
Bertrand, Bernard [Auteur]
Brochet, Eric [Auteur]
Cabanes, Laure [Auteur]
Donal, Erwan [Auteur]
Dubois-Rande, Jean-Luc [Auteur]
Durand-Zaleski, Isabelle [Auteur]
Ernande, Laura [Auteur]
Finet, Gerard [Auteur]
Fraisse, Alain [Auteur]
Giroud, Maurice [Auteur]
Guerin, Patrice [Auteur]
Habib, Gilbert [Auteur]
Juliard, Jean-Michel [Auteur]
LEYS, Didier [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Lievre, Michel [Auteur]
Lusson, Jean-Rene [Auteur]
Marcon, François [Auteur]
Michel, Patrik [Auteur]
Moulin, Thierry [Auteur]
Mounier-Vehier, François [Auteur]
Pierard, Luc A. [Auteur]
Piot, Christophe [Auteur]
Rey, Christian [Auteur]
Rodier, Gilles [Auteur]
Roudaut, Raymond [Auteur]
Schleich, Jean-Marc [Auteur]
Teiger, Emmanuel [Auteur]
Turc, Guillaume [Auteur]
Vuillier, Fabrice [Auteur]
Weimar, Christian [Auteur]
Woimant, France [Auteur]
Chatellier, Gilles [Auteur]
Derumeaux, Genevieve [Auteur]
Amarenco, Pierre [Auteur]
Arquizan, Caroline [Auteur]
Aubry, Pierre [Auteur]
Barthelet, Martine [Auteur]
Bertrand, Bernard [Auteur]
Brochet, Eric [Auteur]
Cabanes, Laure [Auteur]
Donal, Erwan [Auteur]
Dubois-Rande, Jean-Luc [Auteur]
Durand-Zaleski, Isabelle [Auteur]
Ernande, Laura [Auteur]
Finet, Gerard [Auteur]
Fraisse, Alain [Auteur]
Giroud, Maurice [Auteur]
Guerin, Patrice [Auteur]
Habib, Gilbert [Auteur]
Juliard, Jean-Michel [Auteur]
LEYS, Didier [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Lievre, Michel [Auteur]
Lusson, Jean-Rene [Auteur]
Marcon, François [Auteur]
Michel, Patrik [Auteur]
Moulin, Thierry [Auteur]
Mounier-Vehier, François [Auteur]
Pierard, Luc A. [Auteur]
Piot, Christophe [Auteur]
Rey, Christian [Auteur]
Rodier, Gilles [Auteur]
Roudaut, Raymond [Auteur]
Schleich, Jean-Marc [Auteur]
Teiger, Emmanuel [Auteur]
Turc, Guillaume [Auteur]
Vuillier, Fabrice [Auteur]
Weimar, Christian [Auteur]
Woimant, France [Auteur]
Chatellier, Gilles [Auteur]
Titre de la revue :
International journal of stroke . official journal of the International Stroke Society
Nom court de la revue :
Int. J. Stroke
Numéro :
11
Pagination :
724-732
Date de publication :
2016-08-01
ISSN :
1747-4930
Mot(s)-clé(s) en anglais :
transcatheter PFO closure
Ischaemic stroke
patent foramen ovale
antiplatelet therapy
oral anticoagulants
Ischaemic stroke
patent foramen ovale
antiplatelet therapy
oral anticoagulants
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Currently available data do not provide definitive evidence on the comparative benefits of closure of patent foramen ovale, oral anticoagulants and antiplatelet therapy in patients with patent foramen ovale-associated ...
Lire la suite >Currently available data do not provide definitive evidence on the comparative benefits of closure of patent foramen ovale, oral anticoagulants and antiplatelet therapy in patients with patent foramen ovale-associated cryptogenic stroke To assess whether transcatheter patent foramen ovale closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy, for secondary stroke prevention in patients aged 16 to 60 years with a large patent foramen ovale or a patent foramen ovale associated with an atrial septal aneurysm, and an otherwise unexplained ischaemic stroke or retinal ischaemia. Six hundred and sixty-four patients were included in the study. CLOSE is an academic-driven, multicentre, randomized, open-label, three-group, superiority trial with blinded adjudication of outcome events. The trial has been registered with Clinical Trials Register (Clinicaltrials.gov, NCT00562289). Patient recruitment started in December 2007. Patient follow-up will continue until December 2016. Expected mean follow-up = 5.6 years. The primary efficacy outcome is the occurrence of fatal or nonfatal stroke. Safety outcomes include fatal, life-threatening or major procedure- or device-related complications and fatal, life-threatening or major haemorrhagic complications. CLOSE is the first specifically designed trial to assess the superiority of patent foramen ovale closure over antiplatelet therapy alone and the superiority of oral anticoagulants over antiplatelet therapy to prevent stroke recurrence in patients with patent foramen ovale-associated cryptogenic stroke.Lire moins >
Lire la suite >Currently available data do not provide definitive evidence on the comparative benefits of closure of patent foramen ovale, oral anticoagulants and antiplatelet therapy in patients with patent foramen ovale-associated cryptogenic stroke To assess whether transcatheter patent foramen ovale closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy, for secondary stroke prevention in patients aged 16 to 60 years with a large patent foramen ovale or a patent foramen ovale associated with an atrial septal aneurysm, and an otherwise unexplained ischaemic stroke or retinal ischaemia. Six hundred and sixty-four patients were included in the study. CLOSE is an academic-driven, multicentre, randomized, open-label, three-group, superiority trial with blinded adjudication of outcome events. The trial has been registered with Clinical Trials Register (Clinicaltrials.gov, NCT00562289). Patient recruitment started in December 2007. Patient follow-up will continue until December 2016. Expected mean follow-up = 5.6 years. The primary efficacy outcome is the occurrence of fatal or nonfatal stroke. Safety outcomes include fatal, life-threatening or major procedure- or device-related complications and fatal, life-threatening or major haemorrhagic complications. CLOSE is the first specifically designed trial to assess the superiority of patent foramen ovale closure over antiplatelet therapy alone and the superiority of oral anticoagulants over antiplatelet therapy to prevent stroke recurrence in patients with patent foramen ovale-associated cryptogenic stroke.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Équipe(s) de recherche :
Troubles cognitifs dégénératifs et vasculaires
Date de dépôt :
2019-11-27T14:33:14Z